|
39 Companies |
|
49 Products |
|
49 Products |
|
46 Mechanisms of Action |
|
0 Trials |
|
259 News |
|
| «123456» |
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Enrollment change, Combination therapy, Surgery: Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 15, 2015
P2, N=16, Terminated, Sponsor: Roswell Park Cancer Institute
N=30 --> 16
- | gefitinib / Generic mfg.
Enrollment change, Surgery: SWOG-CAN-NCIC-BR19: Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery (clinicaltrials.gov) - Jan 2, 2015
P3, N=503, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 16 N=1242 --> 503
- | gefitinib / Generic mfg.
Trial completion, Surgery: SWOG-CAN-NCIC-BR19: Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery (clinicaltrials.gov) - Dec 31, 2014
P3, N=503, Completed, Sponsor: National Cancer Institute (NCI)
N=1242 --> 503 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date: Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers (clinicaltrials.gov) - Dec 10, 2014
P2, N=40, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Nov 2015
- | Gilotrif (afatinib) / Boehringer Ingelheim
Enrollment change, Metastases: ADAM-Afatinib Diarrhea Assessment and Management (clinicaltrials.gov) - Nov 6, 2014
P3, N=40, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2014 --> Nov 2015 N=80 --> 40
- ||| Avastin (bevacizumab) / Roche
Enrollment open, Monotherapy, Metastases: A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) - Nov 4, 2014
P=N/A, N=200, Recruiting, Sponsor: Hoffmann-La Roche
N=80 --> 40 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Trial completion, Metastases: Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 19, 2014
P2, N=50, Completed, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. (clinicaltrials.gov) - Sep 8, 2014
P2, N=60, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Apr 2015
- Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: GASTO 1001: Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=36, Completed, Sponsor: Si-Yu Wang
Trial primary completion date: Apr 2014 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014
- |||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Metastases: ADAM-Afatinib Diarrhea Assessment and Management (clinicaltrials.gov) - Aug 21, 2014
P3, N=80, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | Trial primary completion date: May 2014 --> Jan 2014 Trial primary completion date: Nov 2014 --> Jan 2016
- bortezomib / Generic mfg.
Trial completion, Enrollment change, Metastases: Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer (clinicaltrials.gov) - Aug 21, 2014
P2, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Jan 2016 Recruiting --> Completed | N=74 --> 42
- ||| Enrollment open: Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=250, Recruiting, Sponsor: Myriad Genetic Laboratories, Inc.
Recruiting --> Completed | N=74 --> 42 Not yet recruiting --> Recruiting
- ||| Enrollment open: ONC003: Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=250, Recruiting, Sponsor: Myriad Genetic Laboratories, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: Photodynamic Therapy in Treating Patients With Lung Cancer (clinicaltrials.gov) - Aug 1, 2014
P1, N=17, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (clinicaltrials.gov) - Jul 24, 2014
P3, N=149, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014
- Pozenveo (poziotinib) / Assertio
Trial primary completion date: NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors (clinicaltrials.gov) - Jul 8, 2014
P2, N=40, Active, not recruiting, Sponsor: National OncoVenture
Active, not recruiting --> Completed | Trial primary completion date: Aug 2013 --> Jul 2014 Trial primary completion date: Dec 2014 --> Sep 2014
- Votrient (pazopanib) / Novartis, BeiGene
Trial termination: Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy (clinicaltrials.gov) - Jul 8, 2014
P3, N=102, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2014 --> Sep 2014 Recruiting --> Terminated; based on IDMC decision
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment change, Trial termination: Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy (clinicaltrials.gov) - Jul 8, 2014
P3, N=102, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Terminated; based on IDMC decision N=600 --> 102 | Recruiting --> Terminated; based on IDMC decision
- |||| ganetespib (ADX-1612) / Aldeyra
Trial primary completion date, Combination therapy, Metastases: Galaxy 2: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (clinicaltrials.gov) - Jun 24, 2014
P3, N=850, Recruiting, Sponsor: Synta Pharmaceuticals Corp.
N=600 --> 102 | Recruiting --> Terminated; based on IDMC decision Trial primary completion date: Oct 2014 --> Mar 2016
- ||||| ganetespib (ADX-1612) / Aldeyra
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Galaxy 2: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (clinicaltrials.gov) - Jun 24, 2014
P3, N=850, Recruiting, Sponsor: Synta Pharmaceuticals Corp.
Trial primary completion date: Oct 2014 --> Mar 2016 N=500 --> 850 | Trial primary completion date: Oct 2014 --> Mar 2016
- || Avastin (bevacizumab) / Roche
New P3 trial: METAL2: Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases (clinicaltrials.gov) - Jun 13, 2014
P3, N=210, Recruiting, Sponsor: Isabelle MONNET
- | Jakafi (ruxolitinib) / Incyte
New P1/2 trial: Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib (clinicaltrials.gov) - Jun 2, 2014
P1/2, N=43, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | gefitinib / Generic mfg.
New P4 trial, Metastases: Combination of Chemotherapy and Gefitinib as First-line Treatment (clinicaltrials.gov) - May 26, 2014
P4, N=60, Recruiting, Sponsor: Bo Jin
- MK-2206 / Merck (MSD)
Trial primary completion date, Metastases: MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy (clinicaltrials.gov) - May 19, 2014
P2, N=82, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=500 --> 850 | Trial primary completion date: Oct 2014 --> Mar 2016 Trial primary completion date: Jun 2014 --> Jun 2015
- sorafenib / Generic mfg.
Trial termination, Metastases: Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 13, 2014
P2, N=11, Terminated, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Jun 2014 --> Jun 2015 Completed --> Terminated
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial initiation date: Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC (clinicaltrials.gov) - May 13, 2014
P1, N=26, Recruiting, Sponsor: Virginia Commonwealth University
Completed --> Terminated Initiation date: Feb 2014 --> Mar 2014
- carboplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment open: Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC (clinicaltrials.gov) - May 13, 2014
P1, N=26, Recruiting, Sponsor: Virginia Commonwealth University
Initiation date: Feb 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- gefitinib / Generic mfg.
Trial primary completion date: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=1, Terminated, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2013 --> Aug 2012
- gefitinib / Generic mfg.
Trial termination: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=1, Terminated, Sponsor: Assistance Publique - H
Trial primary completion date: Sep 2013 --> Aug 2012 Recruiting --> Terminated; Decision of Sponsor
- gefitinib / Generic mfg.
Trial completion date: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=1, Terminated, Sponsor: Assistance Publique - H
Recruiting --> Terminated; Decision of Sponsor Trial completion date: Mar 2014 --> May 2013
- gefitinib / Generic mfg.
Enrollment change: ARPEGE: Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=1, Terminated, Sponsor: Assistance Publique - H
Trial completion date: Mar 2014 --> May 2013 N=60 --> 1
- Trial primary completion date: Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 5, 2014
P1, N=17, Completed, Sponsor: Roswell Park Cancer Institute
N=60 --> 1 Trial primary completion date: Jul 2014 --> Jun 2013
- Trial completion: Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 5, 2014
P1, N=17, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2014 --> Jun 2013 Active, not recruiting --> Completed
- ||| Clinical: Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006) (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=250, Not yet recruiting, Sponsor: Myriad Genetic Laboratories, Inc.
- ||| Clinical: ONC003: Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up (clinicaltrials.gov) - Apr 22, 2014
P=N/A, N=250, Not yet recruiting, Sponsor: Myriad Genetic Laboratories, Inc.
- onartuzumab (RG3638) / Roche
Biomarker, Trial withdrawal: Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- onartuzumab (RG3638) / Roche
Biomarker, Enrollment change: Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=90 --> 0
- Trial termination, Surgery: Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35 (clinicaltrials.gov) - Apr 15, 2014
P2, N=40, Terminated, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
N=90 --> 0 Recruiting --> Terminated; Low levels of recruitment
- ||| Trial completion: Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations. (clinicaltrials.gov) - Apr 10, 2014
P=N/A, N=450, Completed, Sponsor: AstraZeneca
Recruiting --> Terminated; Low levels of recruitment Recruiting --> Completed
- SNX-5422 / Esanex
Enrollment closed: Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma (clinicaltrials.gov) - Apr 7, 2014
P1, N=17, Active, not recruiting, Sponsor: Esanex Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- | gefitinib / Generic mfg.
Enrollment change, Surgery: SWOG-CAN-NCIC-BR19: Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery (clinicaltrials.gov) - Mar 27, 2014
P3, N=1242, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=503 --> 1242
- Trial completion, Metastases: Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages (clinicaltrials.gov) - Mar 27, 2014
P2, N=6, Completed, Sponsor: Roswell Park Cancer Institute
N=503 --> 1242 Active, not recruiting --> Completed
- ||| Avastin (bevacizumab) / Roche
Monotherapy, Metastases: A Study Examining Maintenance Bevacizumab (Avastin (clinicaltrials.gov) - Mar 18, 2014
P=N/A, N=200, Not yet recruiting, Sponsor: Hoffmann-La Roche
- New P1/2 trial, Metastases: Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells (clinicaltrials.gov) - Mar 10, 2014
P1/2, N=40, Recruiting, Sponsor: Fuda Cancer Hospital, Guangzhou
- | Xalkori (crizotinib) / Pfizer
Trial completion, Metastases: Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer (clinicaltrials.gov) - Mar 5, 2014
P1/2, N=27, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=62, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Triapine (3-AP) / Vion, Northwestern University
Trial completion, Metastases: 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=31, Completed, Sponsor: Cancer Therapeutics Research Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carboplatin / Generic mfg., paclitaxel / Generic mfg., gefitinib / Generic mfg.
Trial completion: Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=144, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Metastases: TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tirazone (tirapazamine) / Teclison, SRI International
Trial completion: Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: California Cancer Consortium
Active, not recruiting --> Completed No longer recruiting --> Completed